Production (Stage)
Skye Bioscience, Inc.
SKYE
$1.90
-$0.17-8.21%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.56M | 2.87M | 85.50K | 4.33M | 4.21M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 0.00 | 800.00 | 400.00 | -- |
| Total Operating Expenses | 11.76M | 10.67M | 4.97M | 8.41M | 6.15M |
| Operating Income | -11.76M | -10.67M | -4.97M | -8.41M | -6.15M |
| Income Before Tax | -11.10M | -9.75M | -3.90M | -7.89M | -5.02M |
| Income Tax Expenses | 2.00K | 0.00 | -- | 8.10K | 2.00K |
| Earnings from Continuing Operations | -11.10M | -9.75M | -3.90M | -7.90M | -5.02M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.10M | -9.75M | -3.90M | -7.90M | -5.02M |
| EBIT | -11.76M | -10.67M | -4.97M | -8.41M | -6.15M |
| EBITDA | -11.58M | -10.49M | -4.90M | -8.38M | -6.12M |
| EPS Basic | -0.28 | -0.24 | -0.10 | -0.20 | -0.18 |
| Normalized Basic EPS | -0.18 | -0.15 | -0.07 | -0.13 | -0.14 |
| EPS Diluted | -0.28 | -0.24 | -0.10 | -0.20 | -0.18 |
| Normalized Diluted EPS | -0.18 | -0.15 | -0.07 | -0.13 | -0.14 |
| Average Basic Shares Outstanding | 39.65M | 39.97M | 38.82M | 38.67M | 28.00M |
| Average Diluted Shares Outstanding | 39.65M | 39.97M | 38.82M | 38.67M | 28.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |